Author at Microdose

Robert Toland

I currently work in the regulatory side of Pharmaceutical consulting. I assist companies with their submission process with the FDA or other health agencies (Health Canada, etc.). I generally work with companies that are either in the process of submitting their IND, or with their NDA or BLA.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Science

14 Sep 2022

A Look at MAPS’ Phase 3 Trials

MAPS' second phase 3 trial has been recruited for and is currently in process....

By Robert Toland

Industry

18 Aug 2022

MindMed’s Path Through the Clinical Trial Process

On January 25th, 2022 the Food and Drug Administration (FDA) cleared MindMed’s MM-120 Investigational New Drug (IND), an LSD-based drug directed at treating generalized anxiety disorder, the first of its...

By Robert Toland

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

I currently work in the regulatory side of Pharmaceutical consulting. I assist companies with their submission process with the FDA or other health agencies (Health Canada, etc.). I generally work with companies that are either in the process of submitting their IND, or with their NDA or BLA.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads